A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Novartis Investigative Site, Randwick

Novartis Investigative Site, Westmead

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Adelaide

Novartis Investigative Site, Nedlands

Novartis Investigative Site, New York

Novartis Investigative Site, New York

Novartis Investigative Site, Berlin

Novartis Investigative Site, Pittsburgh

Novartis Investigative Site, Philadelphia

Novartis Investigative Site, Lübeck

Novartis Investigative Site, Madrid

Novartis Investigative Site, Greenville

Novartis Investigative Site, Sarasota

Novartis Investigative Site, Nashville

Novartis Investigative Site, Memphis

Novartis Investigative Site, Seville

Novartis Investigative Site, Columbus

Novartis Investigative Site, Essen

Novartis Investigative Site, Ann Arbor

Novartis Investigative Site, Detroit

Novartis Investigative Site, Lille

Novartis Investigative Site, Oklahoma City

Novartis Investigative Site, Dallas

Novartis Investigative Site, Houston

Novartis Investigative Site, San Antonio

Novartis Investigative Site, Napoli

Novartis Investigative Site, Salt Lake City

Novartis Investigative Site, Scottsdale

Novartis Investigative Site, Goodyear

Novartis Investigative Site, Los Angeles

Novartis Investigative Site, San Francisco

Novartis Investigative Site, Tacoma

Novartis Investigative Site, Tucson

Novartis Investigative Site, Los Angeles

Novartis Investigative Site, Lebanon

Novartis Investigative Site, Nashville

Novartis Investigative Site, Toronto

Novartis Investigative Site, Konin

Novartis Investigative Site, Warsaw

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Headington

Novartis Investigative Site, London